CRIS Current Research Information System

CATANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.497
AS - Asia 5.601
EU - Europa 3.727
SA - Sud America 403
Continente sconosciuto - Info sul continente non disponibili 336
AF - Africa 301
OC - Oceania 12
Totale 16.877
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.364
VN - Vietnam 1.664
SG - Singapore 1.520
CN - Cina 1.169
IT - Italia 790
GB - Regno Unito 785
SE - Svezia 558
DE - Germania 454
HK - Hong Kong 387
BR - Brasile 306
IN - India 257
FR - Francia 240
IE - Irlanda 173
RU - Federazione Russa 168
BD - Bangladesh 110
NL - Olanda 99
FI - Finlandia 88
CA - Canada 80
JP - Giappone 80
TG - Togo 74
UA - Ucraina 74
ZA - Sudafrica 74
KR - Corea 72
CI - Costa d'Avorio 63
EE - Estonia 59
BG - Bulgaria 52
JO - Giordania 50
CH - Svizzera 44
BE - Belgio 40
PH - Filippine 37
TR - Turchia 35
AR - Argentina 34
TW - Taiwan 33
TH - Thailandia 29
ID - Indonesia 26
NG - Nigeria 24
IQ - Iraq 23
IR - Iran 21
EC - Ecuador 20
MX - Messico 19
SC - Seychelles 18
AT - Austria 17
SA - Arabia Saudita 17
PL - Polonia 15
ES - Italia 13
MY - Malesia 13
PK - Pakistan 12
VE - Venezuela 11
AU - Australia 10
LT - Lituania 10
CO - Colombia 9
JM - Giamaica 8
UZ - Uzbekistan 8
CR - Costa Rica 7
CZ - Repubblica Ceca 7
DZ - Algeria 7
EG - Egitto 7
LB - Libano 7
MA - Marocco 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
GR - Grecia 6
PE - Perù 6
RO - Romania 6
ET - Etiopia 5
GT - Guatemala 5
PY - Paraguay 5
TN - Tunisia 5
AZ - Azerbaigian 4
HR - Croazia 4
LV - Lettonia 4
OM - Oman 4
SI - Slovenia 4
AL - Albania 3
AO - Angola 3
BO - Bolivia 3
IL - Israele 3
KE - Kenya 3
KZ - Kazakistan 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
CG - Congo 2
CY - Cipro 2
GH - Ghana 2
HN - Honduras 2
HU - Ungheria 2
KG - Kirghizistan 2
MD - Moldavia 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
BB - Barbados 1
BS - Bahamas 1
Totale 16.526
Salva come PNG Salva come JPEG
Città #
Singapore 1.034
Ashburn 714
Southend 663
San Jose 550
Fairfield 535
Chandler 524
Hong Kong 361
Ho Chi Minh City 360
Hanoi 285
Dong Ket 263
Woodbridge 237
Seattle 235
Houston 230
Wilmington 221
Cambridge 216
Santa Clara 207
Ann Arbor 195
Beijing 195
Dublin 172
Princeton 171
Bologna 162
Boardman 155
Los Angeles 105
Hefei 94
New York 94
Dallas 91
Lauterbourg 85
Milan 83
Lomé 74
Helsinki 68
Nanjing 68
Westminster 66
Abidjan 63
Tokyo 63
Padova 56
Bremen 54
Council Bluffs 52
Seoul 51
Amman 50
Redmond 50
Sofia 50
Jinan 49
Haiphong 48
Munich 47
Da Nang 45
Buffalo 43
Shenyang 43
Turin 43
Berlin 40
Brussels 40
São Paulo 39
Hyderabad 34
Bern 33
Cornaredo 32
Redondo Beach 32
San Diego 31
Saint Petersburg 30
Florence 29
Guangzhou 29
Rome 27
Frankfurt am Main 24
Jacksonville 24
Toronto 24
London 23
Zhengzhou 23
Abeokuta 21
North Bergen 21
Shanghai 21
Clifton 20
Medford 20
Orem 20
Biên Hòa 18
Nanchang 18
Piscataway 18
Burdur 17
Changsha 17
Chicago 17
Redwood City 17
Can Tho 16
Falls Church 16
Hebei 16
Hangzhou 15
San Francisco 15
Brooklyn 14
Hải Dương 14
Norwalk 14
Taiyuan 14
Turku 14
Des Moines 13
Johannesburg 13
Paris 13
Phoenix 13
Quận Bình Thạnh 13
Tianjin 13
Boston 12
Bình Phước 12
Fremont 12
Montreal 12
Stockholm 12
The Dalles 12
Totale 10.377
Salva come PNG Salva come JPEG
Nome #
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 311
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 270
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 264
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 232
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 229
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 228
A novel model of CCl4-induced cirrosi with ascites in the mouse. 227
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 225
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 225
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 214
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 214
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 213
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 213
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 212
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 209
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 207
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 204
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 203
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial 199
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 199
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 198
Platelet lysate enhances the therapeutic activity of Adipose Derived Mesenchymal stromal cells isolated from Crohn disease patients in a novel Mouse model of Colitis 198
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia 193
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 193
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 191
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 188
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 188
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 187
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy 187
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 187
Stem cell mobilization and collection in patients with liver cirrhosis. 186
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 186
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 185
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 185
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 183
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 181
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability 180
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 180
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 180
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 180
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 172
The “vesicular intelligence” strategy of blood cancers 172
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 170
SuperB: A High-Luminosity Asymmetric e+ e- Super Flavor Factory. Conceptual Design Report 169
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 167
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 165
Increased transcription of mitochondrial genes for Complex I in human platelets during ageing 164
CD 133+ stem cells for the treatment of end stage liver disease. 163
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 163
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 159
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 157
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 150
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engrftment. 149
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 149
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product 149
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 148
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 144
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 143
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 142
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 142
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 135
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 135
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 134
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 134
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 132
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 131
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 131
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 130
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 130
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 126
The CD47 pathway is deregulated in human immune thrombocytopenia 123
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 123
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 115
Hollow fiber flow field-flow fractionation enables high-quality Extracellular Vesicle isolation from minimal plasma samples in polycythemia vera liquid biopsy 114
The power of extracellular vesicles in myeloproliferative neoplasms: “Crafting” a microenvironment that matters 112
Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity 109
Validation Study of Analytical Methods for Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia 107
null 107
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 107
CD133+ hematopoietic stem cells reinfusion in end-stage liver disease (ESLD): final results of a phase I clinical trial 107
CD133+ stem cells for the treatment of end-stage liver disease 106
SPONTANEOUS MOBILIZATIONOF BONE MARROW-DERIVED HEMATOPOIETIC AND ENDOTHELAIL PROGENITOR CELLS AFTER ORTHOTOPIC LIVER TRANSPALNTATION (OLT). 104
Is there a gender effect in polycythemia vera? 104
Human T-lymphocyte-derived megakaryocyte colony-stimulating activity 103
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 101
null 98
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 98
null 96
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 95
Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia 90
Reinfusion of highly purified CD133+ stem cells in patients with end-stage liver disease (ESLD): final results of a phase I clinical trial 88
null 86
null 68
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation 66
Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity 59
Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura 56
A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase 56
Ascorbic acid for the treatment of chronic refractory idiopathic thrombocytopenic purpura (ITP) 53
Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: Report of two cases 46
Totale 15.593
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.677
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.677
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.829 118 92 91 194 140 68 48 125 60 203 378 312
2022/20232.094 210 293 120 276 121 175 50 157 367 78 143 104
2023/2024601 48 96 41 75 53 126 27 33 15 41 22 24
2024/20252.286 120 265 205 212 340 113 147 80 86 157 106 455
2025/20265.988 489 445 492 338 582 242 495 427 1.369 586 275 248
2026/2027219 219 0 0 0 0 0 0 0 0 0 0 0
Totale 16.877